A recent study has revealed a concerning trend: a significant number of breast cancer cases are being diagnosed in women under the age of 40. This revelation challenges our understanding of breast cancer and its typical age-related patterns.
The study, presented at the Radiological Society of North America (RSNA) annual meeting, analyzed data from a large community imaging practice in New York. It found that approximately a quarter of all breast cancers diagnosed at this practice involved women under 50, with a notable proportion occurring in those under 40.
What's even more alarming is the aggressive nature of these cancers. Younger patients tend to have higher rates of invasive tumors, triple-negative disease, and grade 3 tumors compared to their slightly older counterparts.
Dr. Stamatia Destounis, who led the study, emphasized the significance of these findings: "It's striking to see that younger women not only bear a substantial burden of breast cancer but also face more aggressive forms of the disease."
The study's implications are far-reaching. It suggests that current screening guidelines, which typically recommend routine screening for women starting at age 40, may need to be reevaluated.
Dr. Destounis concluded, "These findings support the consideration of earlier or more intensive screening for a high-risk younger population."
Recent national data from the CDC and the American Cancer Society also point to a rising incidence of breast cancer in younger women, further emphasizing the need for a re-examination of screening strategies.
Dr. Destounis explained, "Our purpose was to reevaluate age-based screening thresholds and risk stratification strategies, and to understand the specific tumor behavior in these younger patients. How do we detect them? How do we image them? And how can we intervene early?"
The U.S. Preventive Services Task Force and the American Cancer Society currently recommend mammography screening every other year starting at age 40 for average-risk women. However, the study's findings suggest that these guidelines may need to be adjusted to account for the rising incidence and aggressive nature of breast cancer in younger women.
The study analyzed data from 1,798 breast cancers diagnosed among 1,290 women aged 18 to 49 at a community practice in Western New York. The majority of these women were white, and around a fifth had a family history of breast cancer.
Of the cancers diagnosed, a significant proportion (80.6%) were invasive, and a third were grade 3. Most were hormone receptor (HR)-positive/HER2-negative, with smaller percentages being triple-negative, HR-positive/HER2-positive, or HR-negative/HER2-positive.
When asked about genetic testing for BRCA mutations, Dr. Destounis noted that they recommend genetic testing for all newly diagnosed breast cancer patients, especially younger ones. However, most of the patients in the study were not BRCA1 or BRCA2 positive.
"We did find some other genetic mutations," Dr. Destounis added, referring to PALB2 and PTEN mutations.
These findings highlight the complexity of breast cancer and the need for personalized screening and intervention strategies. They also underscore the importance of ongoing research and the need for a nuanced approach to breast cancer screening and treatment, especially for younger women.
